Welcome!

News Feed Item

Data Demonstrating the Ability of ChemoFx® to Identify Platinum-Resistant Primary Ovarian Cancer Patients Prior to Treatment Published by the American Journal of Obstetrics and Gynecology

Precision Therapeutics, a life-science company dedicated to improving patient outcomes in gynecologic cancer, today announced that a study evaluating the ability of the ChemoFx® chemoresponse assay to identify resistance to first-line treatment in ovarian cancer has been accepted for publication by the American Journal of Obstetrics and Gynecology (AJOG).

The study, titled, A Chemoresponse Assay for Prediction of Platinum Resistance in Primary Ovarian Cancer, evaluated the association of ChemoFx® results with disease progression for 276 FIGO stage III-IV ovarian, fallopian and peritoneal cancer patients treated with the standard of care first-line therapy carboplatin/paclitaxel. Patients whose tumors were scored as resistant by the ChemoFx test to carboplatin, were at significantly increased risk of disease progression compared to those with non-resistant tumors (median PFS: 11.8 vs. 16.6 months, respectively, p<0.001). The association was confirmed after adjusting for other clinical factors (HR=1.71, 95% CI=1.12-2.62, p=0.013). In addition to identifying platinum-resistant patients, the study also demonstrated the ability of ChemoFx to identify agents to which a patient’s tumor is sensitive. For 59% of those patients whose tumors proved resistant to carboplatin, at least one other commonly utilized agent was determined by ChemoFx to be sensitive or intermediately sensitive, indicating that these patients may benefit from alternative clinically validated treatments. These results further demonstrate the capability of the ChemoFx test to inform treatment decisions beyond the carboplatin/paclitaxel standard of care, particularly in cases where patients are unlikely to respond to the routine treatment.

Dr. Thomas C. Krivak, M.D., assistant director of gynecologic oncology and director of clinical research in gynecologic oncology at Allegheny Health Network, Department of Obstetrics and Gynecology, in Pittsburgh PA, is the primary author of the study.

“What the findings of this study essentially mean for ovarian cancer patients is that resistance to standard platinum chemotherapy treatment can now be determined much earlier in the treatment pathway with the use of ChemoFx results,” said Dr. Krivak. “Earlier determination of platinum resistance may help physicians choose the more effective treatments upfront, minimizing exposure to ineffective and often expensive therapy. Additionally, having further information about the tumor and chemotherapy resistance could substantiate augmenting standard of care with a third chemotherapy or with targeted agents.”

In addition to these findings, a recent, prospective study on recurrent ovarian cancer patients showed a 14 month improvement in median overall survival when patients were administered treatments identified as sensitive by ChemoFx vs. the non-sensitive treatments. “The combination of information this test provides is invaluable to physicians who are compelled to choose from a range of equivalent treatment recommendations without prior knowledge of how an individual patient may respond to any given treatment,” said Sean McDonald, CEO of Precision. “The ability of this test to determine platinum resistance in primary ovarian cancer patients and to demonstrate longer overall survival by 14 months in recurrent ovarian cancer, makes it an instrumental tool in helping to improve outcomes in ovarian cancer patients.”

About ChemoFx®

ChemoFx® is a proprietary drug response marker, which categorizes an individual patient’s tumor response to a range of standard chemotherapeutic options. Recently published prospective data demonstrates a 14-month improvement in overall survival (OS) when recurrent ovarian cancer patients are treated with therapy indicated as ‘responsive’ by the assay. ChemoFx may also help identify platinum-resistant/refractory primary ovarian patients earlier in their treatment pathway, aiding physicians with the selection of effective treatment upfront for patients newly diagnosed. Precision Therapeutics currently receives ChemoFx® specimens from over 270 top medical institutions including 20 of the 21 National Comprehensive Cancer Network (NCCN) Member Institutions, and 8 of the US News and World Report Top 10 Hospitals for Cancer Care.

About Precision Therapeutics

Precision Therapeutics, a leading life-science company based in Pittsburgh, Pennsylvania, is dedicated to personalizing cancer care and improving patient outcomes. Precision offers a portfolio of products developed to help guide physicians and patients with difficult clinical decisions throughout the cancer care continuum. The company’s other leading products for personalized cancer care include:

  • BioSpeciFx®, a portfolio of clinically relevant molecular tests that provide information about drug response and patient prognosis.
  • GeneFx® Colon, an expression–based gene signature developed for FFPE tissue from stage II colon cancer patients. Following surgery, GeneFx Colon assesses a patient’s risk of recurrence within 5 years.

For more information, visit www.precisiontherapeutics.com.

More Stories By Business Wire

Copyright © 2009 Business Wire. All rights reserved. Republication or redistribution of Business Wire content is expressly prohibited without the prior written consent of Business Wire. Business Wire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Michael Maximilien, better known as max or Dr. Max, is a computer scientist with IBM. At IBM Research Triangle Park, he was a principal engineer for the worldwide industry point-of-sale standard: JavaPOS. At IBM Research, some highlights include pioneering research on semantic Web services, mashups, and cloud computing, and platform-as-a-service. He joined the IBM Cloud Labs in 2014 and works closely with Pivotal Inc., to help make the Cloud Found the best PaaS.
The “Digital Era” is forcing us to engage with new methods to build, operate and maintain applications. This transformation also implies an evolution to more and more intelligent applications to better engage with the customers, while creating significant market differentiators. In both cases, the cloud has become a key enabler to embrace this digital revolution. So, moving to the cloud is no longer the question; the new questions are HOW and WHEN. To make this equation even more complex, most ...
As you move to the cloud, your network should be efficient, secure, and easy to manage. An enterprise adopting a hybrid or public cloud needs systems and tools that provide: Agility: ability to deliver applications and services faster, even in complex hybrid environments Easier manageability: enable reliable connectivity with complete oversight as the data center network evolves Greater efficiency: eliminate wasted effort while reducing errors and optimize asset utilization Security: implemen...
As data explodes in quantity, importance and from new sources, the need for managing and protecting data residing across physical, virtual, and cloud environments grow with it. Managing data includes protecting it, indexing and classifying it for true, long-term management, compliance and E-Discovery. Commvault can ensure this with a single pane of glass solution – whether in a private cloud, a Service Provider delivered public cloud or a hybrid cloud environment – across the heterogeneous enter...
DXWorldEXPO LLC announced today that Kevin Jackson joined the faculty of CloudEXPO's "10-Year Anniversary Event" which will take place on November 11-13, 2018 in New York City. Kevin L. Jackson is a globally recognized cloud computing expert and Founder/Author of the award winning "Cloud Musings" blog. Mr. Jackson has also been recognized as a "Top 100 Cybersecurity Influencer and Brand" by Onalytica (2015), a Huffington Post "Top 100 Cloud Computing Experts on Twitter" (2013) and a "Top 50 C...
Evan Kirstel is an internationally recognized thought leader and social media influencer in IoT (#1 in 2017), Cloud, Data Security (2016), Health Tech (#9 in 2017), Digital Health (#6 in 2016), B2B Marketing (#5 in 2015), AI, Smart Home, Digital (2017), IIoT (#1 in 2017) and Telecom/Wireless/5G. His connections are a "Who's Who" in these technologies, He is in the top 10 most mentioned/re-tweeted by CMOs and CIOs (2016) and have been recently named 5th most influential B2B marketeer in the US. H...
In a world where the internet rules all, where 94% of business buyers conduct online research, and where e-commerce sales are poised to fall between $427 billion and $443 billion by the end of this year, we think it's safe to say that your website is a vital part of your business strategy. Whether you're a B2B company, a local business, or an e-commerce site, digital presence is key to maintain in your drive towards success. Digital Performance will take priority in 2018 for the following reason...
Your homes and cars can be automated and self-serviced. Why can't your storage? From simply asking questions to analyze and troubleshoot your infrastructure, to provisioning storage with snapshots, recovery and replication, your wildest sci-fi dream has come true. In his session at @DevOpsSummit at 20th Cloud Expo, Dan Florea, Director of Product Management at Tintri, provided a ChatOps demo where you can talk to your storage and manage it from anywhere, through Slack and similar services with...
"This week we're really focusing on scalability, asset preservation and how do you back up to the cloud and in the cloud with object storage, which is really a new way of attacking dealing with your file, your blocked data, where you put it and how you access it," stated Jeff Greenwald, Senior Director of Market Development at HGST, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Creating replica copies to tolerate a certain number of failures is easy, but very expensive at cloud-scale. Conventional RAID has lower overhead, but it is limited in the number of failures it can tolerate. And the management is like herding cats (overseeing capacity, rebuilds, migrations, and degraded performance). In his general session at 18th Cloud Expo, Scott Cleland, Senior Director of Product Marketing for the HGST Cloud Infrastructure Business Unit, discussed how a new approach is neces...
What's the role of an IT self-service portal when you get to continuous delivery and Infrastructure as Code? This general session showed how to create the continuous delivery culture and eight accelerators for leading the change. Don Demcsak is a DevOps and Cloud Native Modernization Principal for Dell EMC based out of New Jersey. He is a former, long time, Microsoft Most Valuable Professional, specializing in building and architecting Application Delivery Pipelines for hybrid legacy, and cloud ...
Cloud-enabled transformation has evolved from cost saving measure to business innovation strategy -- one that combines the cloud with cognitive capabilities to drive market disruption. Learn how you can achieve the insight and agility you need to gain a competitive advantage. Industry-acclaimed CTO and cloud expert, Shankar Kalyana presents. Only the most exceptional IBMers are appointed with the rare distinction of IBM Fellow, the highest technical honor in the company. Shankar has also receive...
"With Digital Experience Monitoring what used to be a simple visit to a web page has exploded into app on phones, data from social media feeds, competitive benchmarking - these are all components that are only available because of some type of digital asset," explained Leo Vasiliou, Director of Web Performance Engineering at Catchpoint Systems, in this SYS-CON.tv interview at DevOps Summit at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
"I focus on what we are calling CAST Highlight, which is our SaaS application portfolio analysis tool. It is an extremely lightweight tool that can integrate with pretty much any build process right now," explained Andrew Siegmund, Application Migration Specialist for CAST, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
"We view the cloud not as a specific technology but as a way of doing business and that way of doing business is transforming the way software, infrastructure and services are being delivered to business," explained Matthew Rosen, CEO and Director at Fusion, in this SYS-CON.tv interview at 18th Cloud Expo (http://www.CloudComputingExpo.com), held June 7-9 at the Javits Center in New York City, NY.